Ilaris® · Immunology / Rheumatology / Rare Inflammatory Diseases Ilaris (canakinumab) is a monoclonal antibody that blocks interleukin-1 beta (IL-1β), a key inflammatory cytokine, to reduce inflammation and its downstream effects.
Pulmozyme® · Pulmonology / Respiratory Pulmozyme is a recombinant human DNase that breaks down extracellular DNA in airway secretions to reduce mucus viscosity and improve lung function.
Elizaria® · Multiple Sclerosis Elizaria is a small molecule that targets the S1P1 receptor.
Genolar® + Symbicort® · Respiratory/Pulmonology This combination product pairs a long-acting beta-2 agonist (formoterol) with an inhaled corticosteroid (budesonide) to reduce airway inflammation and improve bronchial smooth muscle relaxation in asthma and COPD.
GNR-060 · Diabetes GNR-060 is a small molecule drug that targets the SGLT2 receptor.
GNR-067 · Diabetes GNR-067 is a small molecule that targets the SGLT2 receptor.
GNR-068 · Diabetes GNR-068 is a small molecule that targets the SGLT2 receptor.
GNR-069 · Diabetes GNR-069 is a small molecule that targets the SGLT2 receptor.
GNR-086 · Diabetes GNR-086 is a small molecule that targets the SGLT2 receptor.
Revelise (GENERIUM, Russia) · Hematology/Oncology Revelise is a recombinant human erythropoietin (EPO) analog that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.
Tigerase® · Diabetes Tigerase is a small molecule that inhibits the activity of a specific enzyme.
Xolair® + Symbicort® · Asthma Xolair (omalizumab) is an anti-IgE antibody that blocks the action of IgE, a protein involved in allergic reactions, while Symbicort (budesonide and formoterol) is a combination of a corticosteroid and a long-acting beta2-adrenergic receptor agonist that reduces inflammation and bronchospasm in the airways.